CompanyHealthAi
Nurix Therapeutics
Nurix Therapeutics is a clinical-stage biopharmaceutical company in San Francisco pioneering targeted protein degradation - medicines that destroy disease-causing proteins rather than merely blocking them. Built on its DELigase discovery engine that harnesses the cell's ubiquitin-proteasome system and DNA-encoded library screening, Nurix is advancing a pipeline of degraders and degrader antibody conjugates for cancer and autoimmune disease, led by the BTK degrader bexobrutideg (NX-5948). The company is partnered with Roche, Sanofi, Gilead, and Pfizer (via Seagen) and trades on Nasdaq under NRIX.
2009Founded
San FranciscoHQ
$209 million (gross; ~$238.5M with overallotment)IPO (Nasdaq: NRIX)
targeted protein degradationbiotechbiopharmaceuticaloncologyautoimmune diseasee3 ligase